SCHEDULE 13G/A: Star Irrevocable Trust #1 Discloses 6.9% Stake in Design Therapeutics, Inc. via Amended Schedule 13G Filing
Beneficial Ownership Report (Schedule 13G Amendment)
An amended Schedule 13G filing reveals that Star Irrevocable Trust #1 holds a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.
Summary
- Star Irrevocable Trust #1 dated April 22, 2019, and Jason Howerton are the reporting persons in this Schedule 13G Amendment No. 1 filing.
- As of December 31, 2024, Star Irrevocable Trust #1 beneficially owns 3,834,355 shares of Common Stock of Design Therapeutics, Inc.
- This ownership represents 6.9% of the total outstanding Common Stock of Design Therapeutics, Inc.
- The percentage is calculated based on 56,621,037 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.
- Star Irrevocable Trust #1 holds shared voting power and shared dispositive power over all 3,834,355 shares.
- Jason Howerton, who was the sole trustee of Star Irrevocable Trust #1 until October 1, 2024, reports 0 shares beneficially owned and no voting or dispositive power as of the filing date.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership, common in the financial industry for transparency regarding significant shareholder positions. It does not provide specific industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake in the company, which can inform investment decisions.
Key Dates
| Date | Description |
|---|---|
| October 1, 2024 | Jason Howerton ceased being the sole trustee of Star Irrevocable Trust #1. |
| November 4, 2024 | Date as of which 56,621,037 shares of Common Stock were outstanding, used for percentage calculation. |
| November 7, 2024 | Date Design Therapeutics, Inc. filed its Quarterly Report on Form 10-Q. |
| December 31, 2024 | Date of event which requires the filing of this Schedule 13G Amendment No. 1. |
| February 7, 2025 | Signature date for Star Irrevocable Trust #1 and Jason Howerton on the filing. |
Keywords
Design Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Disclosure, Star Irrevocable Trust #1, Jason Howerton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.